| Clinically isolated syndrome
Ocrevus vs Rebif
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Ocrevus vs Rebif with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRebif has a higher rate of injection site reactions vs Ocrevus based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rebif but not Ocrevus, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ocrevus
Rebif
At A Glance
IV infusion
Every 6 months
CD20 antagonist
SC injection
Three times per week
Interferon beta-1a
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive Initial dose: 300 mg IV infusion, followed two weeks later by a second 300 mg IV infusion; subsequent doses: 600 mg IV infusion every 6 months.
Clinically isolated syndrome, Multiple Sclerosis Relapsing-Remitting, Multiple Sclerosis Secondary Progressive 22 mcg or 44 mcg SC three times per week; titrate starting at 20% of prescribed dose over a 4-week period to the targeted dose; administer at the same time on the same three days at least 48 hours apart each week.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to OCREVUS
- History of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation
Adverse Reactions
Most common (>=10%) Upper respiratory tract infections, infusion reactions, skin infections, lower respiratory tract infections
Serious Infusion reactions, infections, progressive multifocal leukoencephalopathy, reduction in immunoglobulins, malignancies, immune-mediated colitis, liver injury
Postmarketing Immune-mediated colitis, liver injury, serious herpes infections, progressive multifocal leukoencephalopathy, babesiosis, pyoderma gangrenosum
Most common Injection site reaction, influenza-like symptoms, headache, fatigue, fever, leukopenia, elevated liver enzymes (SGPT, SGOT), myalgia, back pain, abdominal pain, depression
Serious Depression and suicide, hepatic injury, anaphylaxis and other allergic reactions, injection site necrosis, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, seizures
Postmarketing Drug-induced lupus erythematosus, autoimmune hepatitis, retinal vascular disorders, pulmonary arterial hypertension, erythema multiforme, Stevens-Johnson syndrome, hemolytic anemia
Pharmacology
CD20 antagonist; ocrelizumab is a recombinant humanized IgG1 monoclonal antibody that binds to CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis.
Interferon beta-1a; the exact mechanism(s) by which REBIF exerts its therapeutic effects in multiple sclerosis is unknown, but it is a recombinant form of human interferon beta produced in Chinese Hamster Ovary cells with an amino acid sequence identical to natural fibroblast-derived human interferon beta.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ocrevus
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rebif
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Ocrevus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rebif
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Ocrevus
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Rebif
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OcrevusView full Ocrevus profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.